Do analysts recommend DTSQ or EVAX?

Evaxion A/S has a consensus price target of $11.00, suggesting a potential upside of 249.21%. Given Evaxion A/S's stronger consensus rating and higher probable upside, analysts clearly believe Evaxion A/S is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Evaxion A/S 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has stronger valuation and earnings, DTSQ or EVAX?

DT Cloud Star Acquisition has higher earnings, but lower revenue than Evaxion A/S. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DT Cloud Star Acquisition N/A N/A N/A N/A N/A Evaxion A/S $7.53M 3.49 -$7.71M -$1.47 N/A

Is DTSQ or EVAX more profitable?

DT Cloud Star Acquisition's return on equity of 0.00% beat Evaxion A/S's return on equity. Company Net Margins Return on Equity Return on Assets DT Cloud Star Acquisition N/A N/A N/A Evaxion A/S N/A -73.56% -37.45%

Does the media refer more to DTSQ or EVAX?

In the previous week, Evaxion A/S had 2 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 4 mentions for Evaxion A/S and 2 mentions for DT Cloud Star Acquisition. DT Cloud Star Acquisition's average media sentiment score of 1.92 beat Evaxion A/S's score of -0.90 indicating that DT Cloud Star Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DT Cloud Star Acquisition 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Evaxion A/S 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts rate PCSC or EVAX?

Evaxion A/S has a consensus target price of $11.00, indicating a potential upside of 249.21%. Given Evaxion A/S's stronger consensus rating and higher possible upside, analysts clearly believe Evaxion A/S is more favorable than Perceptive Capital Solutions. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Perceptive Capital Solutions 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evaxion A/S 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is PCSC or EVAX more profitable?

Perceptive Capital Solutions' return on equity of -2.70% beat Evaxion A/S's return on equity. Company Net Margins Return on Equity Return on Assets Perceptive Capital Solutions N/A -2.70% -0.84% Evaxion A/S N/A -73.56% -37.45%

Is EVAX or RANI more profitable?

Evaxion A/S's return on equity of -73.56% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Evaxion A/S N/A -73.56% -37.45% Rani Therapeutics N/A -104.60% -65.17%

Does the media prefer EVAX or RANI?

In the previous week, Rani Therapeutics had 3 more articles in the media than Evaxion A/S. MarketBeat recorded 7 mentions for Rani Therapeutics and 4 mentions for Evaxion A/S. Rani Therapeutics' average media sentiment score of 0.92 beat Evaxion A/S's score of -0.90 indicating that Rani Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evaxion A/S 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Rani Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ONCY or EVAX more profitable?

Evaxion A/S's return on equity of -73.56% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Oncolytics Biotech N/A -2,185.97% -442.99% Evaxion A/S N/A -73.56% -37.45%

Does the media favor ONCY or EVAX?

In the previous week, Evaxion A/S had 1 more articles in the media than Oncolytics Biotech. MarketBeat recorded 4 mentions for Evaxion A/S and 3 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of -0.52 beat Evaxion A/S's score of -0.90 indicating that Oncolytics Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncolytics Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Evaxion A/S 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Is EVAX or KLRS more profitable?

Kalaris Therapeutics' return on equity of -71.71% beat Evaxion A/S's return on equity. Company Net Margins Return on Equity Return on Assets Evaxion A/S N/A -73.56% -37.45% Kalaris Therapeutics N/A -71.71% -42.95%

Does the media refer more to EVAX or KLRS?

In the previous week, Evaxion A/S had 3 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 4 mentions for Evaxion A/S and 1 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.00 beat Evaxion A/S's score of -0.90 indicating that Kalaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evaxion A/S 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Kalaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Live Earnings Conference Call: Evaxion A/S's Q2 2026 earnings call is happening now. Listen live.

Evaxion A/S (EVAX) Competitors

$3.15 0.00 (0.00%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$3.32 +0.17 (+5.27%)

As of 09:25 AM Eastern

Compare

EVAX vs. DTSQ, PCSC, RANI, ONCY, and KLRS

Should you buy Evaxion A/S stock or one of its competitors? Evaxion A/S's main competitors and comparable companies include DT Cloud Star Acquisition (DTSQ), Perceptive Capital Solutions (PCSC), Rani Therapeutics (RANI), Oncolytics Biotech (ONCY), and Kalaris Therapeutics (KLRS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Evaxion A/S compare to DT Cloud Star Acquisition?

DT Cloud Star Acquisition (NASDAQ:DTSQ) and Evaxion A/S (NASDAQ:EVAX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Evaxion A/S has a consensus price target of $11.00, suggesting a potential upside of 249.21%. Given Evaxion A/S's stronger consensus rating and higher probable upside, analysts clearly believe Evaxion A/S is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

11.0% of Evaxion A/S shares are held by institutional investors. 52.9% of DT Cloud Star Acquisition shares are held by company insiders. Comparatively, 41.6% of Evaxion A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

DT Cloud Star Acquisition's return on equity of 0.00% beat Evaxion A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DT Cloud Star Acquisition	N/A	N/A	N/A
Evaxion A/S	N/A	-73.56%	-37.45%

DT Cloud Star Acquisition has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

In the previous week, Evaxion A/S had 2 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 4 mentions for Evaxion A/S and 2 mentions for DT Cloud Star Acquisition. DT Cloud Star Acquisition's average media sentiment score of 1.92 beat Evaxion A/S's score of -0.90 indicating that DT Cloud Star Acquisition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DT Cloud Star Acquisition	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Evaxion A/S	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

DT Cloud Star Acquisition has higher earnings, but lower revenue than Evaxion A/S.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A
Evaxion A/S	$7.53M	3.49	-$7.71M	-$1.47	N/A

Summary

Evaxion A/S beats DT Cloud Star Acquisition on 7 of the 11 factors compared between the two stocks.

How does Evaxion A/S compare to Perceptive Capital Solutions?

Perceptive Capital Solutions (NASDAQ:PCSC) and Evaxion A/S (NASDAQ:EVAX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

Perceptive Capital Solutions' return on equity of -2.70% beat Evaxion A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perceptive Capital Solutions	N/A	-2.70%	-0.84%
Evaxion A/S	N/A	-73.56%	-37.45%

Perceptive Capital Solutions has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

Evaxion A/S has a consensus target price of $11.00, indicating a potential upside of 249.21%. Given Evaxion A/S's stronger consensus rating and higher possible upside, analysts clearly believe Evaxion A/S is more favorable than Perceptive Capital Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perceptive Capital Solutions	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Perceptive Capital Solutions has higher earnings, but lower revenue than Evaxion A/S. Perceptive Capital Solutions is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perceptive Capital Solutions	N/A	N/A	$840K	-$0.06	N/A
Evaxion A/S	$7.53M	3.49	-$7.71M	-$1.47	N/A

In the previous week, Evaxion A/S had 4 more articles in the media than Perceptive Capital Solutions. MarketBeat recorded 4 mentions for Evaxion A/S and 0 mentions for Perceptive Capital Solutions. Perceptive Capital Solutions' average media sentiment score of 0.00 beat Evaxion A/S's score of -0.90 indicating that Perceptive Capital Solutions is being referred to more favorably in the media.

Company	Overall Sentiment
Perceptive Capital Solutions	Neutral
Evaxion A/S	Negative

11.0% of Evaxion A/S shares are owned by institutional investors. 22.1% of Perceptive Capital Solutions shares are owned by company insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Evaxion A/S beats Perceptive Capital Solutions on 8 of the 14 factors compared between the two stocks.

How does Evaxion A/S compare to Rani Therapeutics?

Evaxion A/S (NASDAQ:EVAX) and Rani Therapeutics (NASDAQ:RANI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

Evaxion A/S has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

Evaxion A/S presently has a consensus price target of $11.00, suggesting a potential upside of 249.21%. Rani Therapeutics has a consensus price target of $8.75, suggesting a potential upside of 854.61%. Given Rani Therapeutics' higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Evaxion A/S's return on equity of -73.56% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-73.56%	-37.45%
Rani Therapeutics	N/A	-104.60%	-65.17%

11.0% of Evaxion A/S shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by company insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Evaxion A/S has higher revenue and earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	3.49	-$7.71M	-$1.47	N/A
Rani Therapeutics	$1.63M	69.66	-$29.67M	-$0.27	N/A

In the previous week, Rani Therapeutics had 3 more articles in the media than Evaxion A/S. MarketBeat recorded 7 mentions for Rani Therapeutics and 4 mentions for Evaxion A/S. Rani Therapeutics' average media sentiment score of 0.92 beat Evaxion A/S's score of -0.90 indicating that Rani Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evaxion A/S	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Rani Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Rani Therapeutics beats Evaxion A/S on 7 of the 13 factors compared between the two stocks.

How does Evaxion A/S compare to Oncolytics Biotech?

Oncolytics Biotech (NASDAQ:ONCY) and Evaxion A/S (NASDAQ:EVAX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by company insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Oncolytics Biotech currently has a consensus target price of $5.00, indicating a potential upside of 501.68%. Evaxion A/S has a consensus target price of $11.00, indicating a potential upside of 249.21%. Given Oncolytics Biotech's higher probable upside, analysts plainly believe Oncolytics Biotech is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Evaxion A/S's return on equity of -73.56% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-2,185.97%	-442.99%
Evaxion A/S	N/A	-73.56%	-37.45%

In the previous week, Evaxion A/S had 1 more articles in the media than Oncolytics Biotech. MarketBeat recorded 4 mentions for Evaxion A/S and 3 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of -0.52 beat Evaxion A/S's score of -0.90 indicating that Oncolytics Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncolytics Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Evaxion A/S	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Oncolytics Biotech has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market.

Evaxion A/S has higher revenue and earnings than Oncolytics Biotech. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.34	N/A
Evaxion A/S	$7.53M	3.49	-$7.71M	-$1.47	N/A

Summary

Evaxion A/S beats Oncolytics Biotech on 9 of the 14 factors compared between the two stocks.

How does Evaxion A/S compare to Kalaris Therapeutics?

Evaxion A/S (NASDAQ:EVAX) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

Evaxion A/S has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market.

Evaxion A/S has higher revenue and earnings than Kalaris Therapeutics. Evaxion A/S is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	3.49	-$7.71M	-$1.47	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A

In the previous week, Evaxion A/S had 3 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 4 mentions for Evaxion A/S and 1 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.00 beat Evaxion A/S's score of -0.90 indicating that Kalaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evaxion A/S	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Kalaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kalaris Therapeutics' return on equity of -71.71% beat Evaxion A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-73.56%	-37.45%
Kalaris Therapeutics	N/A	-71.71%	-42.95%

11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by company insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Evaxion A/S presently has a consensus price target of $11.00, suggesting a potential upside of 249.21%. Kalaris Therapeutics has a consensus price target of $18.75, suggesting a potential upside of 349.64%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kalaris Therapeutics is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Kalaris Therapeutics beats Evaxion A/S on 9 of the 15 factors compared between the two stocks.

Get Evaxion A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVAX vs. The Competition

Export

Metric	Evaxion A/S	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$26.27M	$3.89B	$7.18B	$12.87B
Dividend Yield	N/A	3.66%	2.55%	10.29%
P/E Ratio	-2.14	11.71	268.94	24.23
Price / Sales	3.49	1,349.97	618.72	100.21
Price / Cash	N/A	102.56	78.23	52.73
Price / Book	1.54	17.33	13.28	6.25
Net Income	-$7.71M	-$12.52M	$3.47B	$348.04M
7 Day Performance	-3.23%	4.47%	2.21%	-0.17%
1 Month Performance	7.14%	7.81%	5.29%	2.66%
1 Year Performance	6.78%	63.80%	29.17%	21.01%

Evaxion A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVAX Evaxion A/S	2.8915 of 5 stars	$3.15 flat	$11.00 +249.2%	+3.6%	$26.27M	$7.53M	N/A	60	Gap Down High Trading Volume
DTSQ DT Cloud Star Acquisition	2.0842 of 5 stars	$11.31 +0.4%	N/A	+8.5%	$100.22M	N/A	N/A	N/A	News Coverage
PCSC Perceptive Capital Solutions	0.1104 of 5 stars	$11.95 flat	N/A	N/A	$97.48M	N/A	N/A	N/A
RANI Rani Therapeutics	3.7999 of 5 stars	$0.79 +1.0%	$8.75 +1,014.6%	+66.9%	$96.25M	$1.63M	N/A	110	Positive News Earnings Report Analyst Forecast
ONCY Oncolytics Biotech	1.6456 of 5 stars	$0.82 +2.1%	$8.50 +936.6%	-16.7%	$95.82M	N/A	N/A	30	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVAX) was last updated on 8/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evaxion A/S (EVAX) Competitors

EVAX vs. DTSQ, PCSC, RANI, ONCY, and KLRS

How does Evaxion A/S compare to DT Cloud Star Acquisition?

Summary

How does Evaxion A/S compare to Perceptive Capital Solutions?

Summary

How does Evaxion A/S compare to Rani Therapeutics?

Summary

How does Evaxion A/S compare to Oncolytics Biotech?

Summary

How does Evaxion A/S compare to Kalaris Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVAX vs. The Competition

Evaxion A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evaxion A/S (EVAX) Competitors

EVAX vs. DTSQ, PCSC, RANI, ONCY, and KLRS

How does Evaxion A/S compare to DT Cloud Star Acquisition?

Do analysts recommend DTSQ or EVAX?

Do institutionals & insiders hold more shares of DTSQ or EVAX?

Is DTSQ or EVAX more profitable?

Which has more risk and volatility, DTSQ or EVAX?

Does the media refer more to DTSQ or EVAX?

Which has stronger valuation and earnings, DTSQ or EVAX?

Summary

How does Evaxion A/S compare to Perceptive Capital Solutions?

Is PCSC or EVAX more profitable?

Which has more risk & volatility, PCSC or EVAX?

Do analysts rate PCSC or EVAX?

Which has stronger earnings and valuation, PCSC or EVAX?

Does the media favor PCSC or EVAX?

Do insiders & institutionals believe in PCSC or EVAX?

Summary

How does Evaxion A/S compare to Rani Therapeutics?

Which has more risk and volatility, EVAX or RANI?

Do analysts rate EVAX or RANI?

Is EVAX or RANI more profitable?

Do institutionals and insiders hold more shares of EVAX or RANI?

Which has better earnings & valuation, EVAX or RANI?

Does the media prefer EVAX or RANI?

Summary

How does Evaxion A/S compare to Oncolytics Biotech?

Do insiders and institutionals believe in ONCY or EVAX?

Do analysts recommend ONCY or EVAX?

Is ONCY or EVAX more profitable?

Does the media favor ONCY or EVAX?

Which has more volatility & risk, ONCY or EVAX?

Which has preferable earnings & valuation, ONCY or EVAX?

Summary

How does Evaxion A/S compare to Kalaris Therapeutics?

Which has more volatility and risk, EVAX or KLRS?

Which has stronger earnings and valuation, EVAX or KLRS?

Does the media refer more to EVAX or KLRS?

Is EVAX or KLRS more profitable?

Do insiders & institutionals have more ownership in EVAX or KLRS?

Do analysts recommend EVAX or KLRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVAX vs. The Competition

Evaxion A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools